Navigation Links
Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
Date:9/6/2012

ROCKVILLE, Md., Sept. 6, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has granted the first licenses for use of its Spinal Cord Delivery Platform and Floating Cannula, for delivering therapeutic agents to the spinal cord, to Salt Lake City-based Q Therapeutics. This platform and cannula have been in use since 2010, in the recently completed Phase I ALS trial delivering Neuralstem's NSI-566 neural stem cells into the spinal cords of patients with amyotrophic lateral sclerosis, (ALS or Lou Gehrig's disease). The devices have been demonstrated to be safe in the 18 industry-leading surgeries. Neuralstem holds the exclusive worldwide licenses to the surgical devices. The financial terms of the agreement were not disclosed.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"This is the beginning of a new paradigm in treating multiple indications for spinal cord diseases," said Richard Garr, Neuralstem's President and CEO.  "Intraspinal delivery of therapeutics has long been thought to pose problems too difficult to overcome. However, we have established compelling safety data in our first-in-human, 18-patient trial, and we expect to continue to license out the surgical devices to both industry and academia as they now begin to explore the possibilities our technology has enabled."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition t
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
7. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
8. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
9. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
10. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
11. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo ... a medical device company developing its Symphony® CGM ... system, today announced that Robert F. Doman ... Therapeutics, will present at "TEN", Noble Financial Capital ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ... insulin delivery systems especially for type 1 ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ... aspects in today,s growth in the pharmaceutical ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Microfluidic Systems, a privately-held company, announced today ... Magazine . The Fourth Annual Exclusive ... . 5000 ranked Microfluidic Systems number 3035 with ... the most comprehensive look at the most important ...
... 24 Argos Therapeutics today announced ... study for the treatment of renal cell carcinoma (RCC) have ... Kidney Cancer Symposium on Oct. 1-2 in Chicago. ... 25 patients with newly diagnosed metastatic clear cell RCC.  Post-nephrectomy, ...
Cached Medicine Technology:Microfluidic Systems (MFSI) Receives Award from Inc. Magazine 2Results From Argos Therapeutics' Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium 2
(Date:4/16/2014)... A team that includes scientists from the School ... Center at San Antonio, Johns Hopkins University and St. ... helps a common fungus to infect the body. , ... infections, diaper rashes and oral thrush, and is the ... also cause a life-threatening infection of the blood called ...
(Date:4/15/2014)... CORVALLIS, Ore. Handling frozen fish caused nearly half ... quarter of the injuries on freezer-longliner vessels operating off ... University shows. , Many of those injuries and others ... with the right interventions, and the research methods used ... and fatalities in other types of commercial fishing, said ...
(Date:4/14/2014)... made in chemotherapy over the past decade, but targeting ... to be a major challenge. , Nanotechnology has ... use of nanocarriers, or capsules, that can transport cargoes ... , The catch? These carriers are tiny, and it ... from 10 nanometers to 100 nanometers, and the drugs ...
(Date:4/14/2014)... Penicillin, one of the scientific marvels of the 20th ... once won against bacterial infections. But scientists at the ... approach to restoring its combat effectiveness, even against so-called ... power of the penicillin family of drugs since their ... example, the staph infection, brought about by the bacterium ...
(Date:4/14/2014)... 2014 Popular web information on colorectal cancer is ... doesn,t address the appropriate risks to and concerns of ... suggests. , In a review of a dozen popular ... colorectal cancer screening were written beyond the recommended sixth-grade ... address key risks, as well as the barriers to ...
Breaking Medicine News(10 mins):Health News:Changes in processing, handling could reduce commercial fishing injuries 2Health News:Nano shake-up 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3
... home residents with advanced dementia, a terminal illness, is ... of limited clinical benefit, according to a new study ... Harvard Medical School, published in the online version of ... 10, 2011. , The study examined Medicare expenditures for ...
... January 10, 2011 -- Previous research regarding the association ... later life suggests that mild to moderate alcohol consumption ... research has been conducted on subjects already rather elderly ... published in the December issue of the Journal ...
... The H1N1 swine flu pandemic last winter offers clues ... against multiple strains of influenza, U.S. researchers say. They ... and recovered had a special immune response, producing antibodies that ... virus matched typical influenza strains only in components that are ...
... HealthDay Reporter , MONDAY, Jan. 10 (HealthDay News) -- Patients ... by bleeding in the brain may be at an increased ... It is well-known that statins help reduce the risk ... a blood vessel in the brain. However, whether statins also ...
... masculine, women in their fertile phase are more likely ... with George Clooney types. But women with masculine-looking ... partners, a recent study co-authored by a University of ... intelligence has no effect on the extent to which ...
... protein that plays an important role in some antioxidant therapies ... cause it to promote atherosclerosis, or clogging of the arteries. ... journal Arteriosclerosis, Thrombosis and Vascular Biology , the finding ... not yielded more positive results. The protein, ...
Cached Medicine News:Health News:Aggressive care raises Medicare costs in end-stage dementia 2Health News:Aggressive care raises Medicare costs in end-stage dementia 3Health News:Abstinence, heavy drinking, binge drinking associated with increased risk of cognitive impairment 2Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:Statins May Be Harmful After Stroke 2Health News:Statins May Be Harmful After Stroke 3Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: